BioCentury | Jan 27, 2021
Management Tracks

Novartis’ chief digital officer stepping down; plus moves at Taysha, Roivant, Faze and more

...AG. Bernard Courtieu joined theranostic and genomics company OncoDNA S.A. as CEO. Courtieu was CEO of IntegraGen...
BioCentury | Feb 23, 2015
Company News

IntegraGen S.A, Esperite deal

...screening tools. IntegraGen declined to provide financial details, and Genoma did not respond to inquiries. IntegraGen...
BioCentury | Apr 14, 2014
Company News

IntegraGen, Pfizer deal

...IntegraGen said it granted Pfizer access to evaluate IntegraGen's 56-gene molecular signature to predict clinical prognosis...
...IntegraGen said terms of the agreement are not disclosed. The companies declined to provide details. IntegraGen S.A....
BioCentury | Mar 31, 2014
Company News

IntegraGen, Institut Gustave Roussy pharmacogenetics, genomics news

...Next quarter, IntegraGen will install and operate on behalf of the institute a high throughput, large-scale...
...will be used within the framework of personalized medicine cancer programs developed by the institute. IntegraGen...
...will share IP generated from an ongoing research-based partnership. IntegraGen declined to disclose financial details. IntegraGen S.A....
BioCentury | Jan 27, 2014
Company News

IntegraGen, University of Southampton deal

...cetuximab in 272 K-Ras ( KRAS )-wild type patients with operable metastases from colorectal cancer. IntegraGen...
...anti- EGFR therapy. IntegraGen said the terms of the deal are not disclosed. Last year, IntegraGen...
...except in Japan where the three companies market the drug (see BioCentury, Oct. 21, 2013). IntegraGen S.A....
BioCentury | Oct 21, 2013
Company News

IntegraGen, Assistance Publique - Hopitaux de Paris, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Pa

...treated with anti- EGFR therapy. The company did not provide comment in time for publication. IntegraGen S.A....
BioCentury | Mar 4, 2013
Company News

IntegraGen, Lab21 deal

...Lab21 and IntegraGen partnered to develop a microRNA assay for colorectal cancer. Lab21 will use its...
...to develop the assay to detect expression levels of the miRNA biomarker hsa-miR-31-3p discovered by IntegraGen...
...to EGFR inhibitor therapy in K-Ras wild-type patients with metastatic colorectal cancer. The companies said IntegraGen...
BioCentury | Mar 26, 2012
Clinical News

ARISk update

...suspected to have an autism spectrum disorder, 75 children with ADHD and 225 healthy children. IntegraGen S.A....
BioCentury | Dec 19, 2011
Company News

IntegraGen management update

IntegraGen S.A. (Euronext:ALINT), Every, France Business: Diagnostic, Pharmacogenetics Hired: Laurence Lamotte as CFO, formerly CFO of Aureus Sciences WIR Staff Diagnostic...
BioCentury | May 30, 2011
Financial News

IntegraGen proposes private placement

IntegraGen S.A. (Euronext:ALINT), Evry, France Business: Diagnostic, Pharmacogenetics Date announced: 5/25/11 Type: Private placement To be raised: €2.5 million ($3.5 million) Shares: TBD Price prior: €9.13 Shares outstanding prior: 3.8 million WIR Staff Diagnostic...
Items per page:
1 - 10 of 36
BioCentury | Jan 27, 2021
Management Tracks

Novartis’ chief digital officer stepping down; plus moves at Taysha, Roivant, Faze and more

...AG. Bernard Courtieu joined theranostic and genomics company OncoDNA S.A. as CEO. Courtieu was CEO of IntegraGen...
BioCentury | Feb 23, 2015
Company News

IntegraGen S.A, Esperite deal

...screening tools. IntegraGen declined to provide financial details, and Genoma did not respond to inquiries. IntegraGen...
BioCentury | Apr 14, 2014
Company News

IntegraGen, Pfizer deal

...IntegraGen said it granted Pfizer access to evaluate IntegraGen's 56-gene molecular signature to predict clinical prognosis...
...IntegraGen said terms of the agreement are not disclosed. The companies declined to provide details. IntegraGen S.A....
BioCentury | Mar 31, 2014
Company News

IntegraGen, Institut Gustave Roussy pharmacogenetics, genomics news

...Next quarter, IntegraGen will install and operate on behalf of the institute a high throughput, large-scale...
...will be used within the framework of personalized medicine cancer programs developed by the institute. IntegraGen...
...will share IP generated from an ongoing research-based partnership. IntegraGen declined to disclose financial details. IntegraGen S.A....
BioCentury | Jan 27, 2014
Company News

IntegraGen, University of Southampton deal

...cetuximab in 272 K-Ras ( KRAS )-wild type patients with operable metastases from colorectal cancer. IntegraGen...
...anti- EGFR therapy. IntegraGen said the terms of the deal are not disclosed. Last year, IntegraGen...
...except in Japan where the three companies market the drug (see BioCentury, Oct. 21, 2013). IntegraGen S.A....
BioCentury | Oct 21, 2013
Company News

IntegraGen, Assistance Publique - Hopitaux de Paris, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Pa

...treated with anti- EGFR therapy. The company did not provide comment in time for publication. IntegraGen S.A....
BioCentury | Mar 4, 2013
Company News

IntegraGen, Lab21 deal

...Lab21 and IntegraGen partnered to develop a microRNA assay for colorectal cancer. Lab21 will use its...
...to develop the assay to detect expression levels of the miRNA biomarker hsa-miR-31-3p discovered by IntegraGen...
...to EGFR inhibitor therapy in K-Ras wild-type patients with metastatic colorectal cancer. The companies said IntegraGen...
BioCentury | Mar 26, 2012
Clinical News

ARISk update

...suspected to have an autism spectrum disorder, 75 children with ADHD and 225 healthy children. IntegraGen S.A....
BioCentury | Dec 19, 2011
Company News

IntegraGen management update

IntegraGen S.A. (Euronext:ALINT), Every, France Business: Diagnostic, Pharmacogenetics Hired: Laurence Lamotte as CFO, formerly CFO of Aureus Sciences WIR Staff Diagnostic...
BioCentury | May 30, 2011
Financial News

IntegraGen proposes private placement

IntegraGen S.A. (Euronext:ALINT), Evry, France Business: Diagnostic, Pharmacogenetics Date announced: 5/25/11 Type: Private placement To be raised: €2.5 million ($3.5 million) Shares: TBD Price prior: €9.13 Shares outstanding prior: 3.8 million WIR Staff Diagnostic...
Items per page:
1 - 10 of 36